Dermatitis Research Review, Issue 5

In this issue:

Children hospitalised for AD at increased risk of being medicated for psychiatric disorders
Topical corticosteroid treatment improves both skin and systematic immune dysfunction
Serum immunoinflammatory biomarkers may be prognostic for disease severity
Dupilumab combinations elicit response in disease recalcitrant to dupilumab monotherapy
Biological therapies for AD
Early and long-term effects of dupilumab treatment on circulating T cell functions
Comparative safety of systemic immunomodulatory medications
Is dupilumab safe to use during pregnancy?
Are eosinophil relative count and neutrophil–lymphocyte ratio biomarkers of disease severity?
How does COVID-19 impact patients undergoing dupilumab therapy?

Please login below to download this issue (PDF)

Subscribe